Promising preclinical trials investigating the role of IGF1R as a therapeutical target has resulted in the initiating of clinical trials on patients with multiple myeloma.[75]There are studies[76] suggesting IGF1R as a potential target in NSCLC treatment. This evidence concerns the gene IGF1R and AL amyloidosis.